Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Eur J Immunol ; 44(7): 2059-63, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24700174

RESUMO

Several mechanisms account for the beneficial effect of intravenous immunoglobulin (IVIg) in autoimmune and inflammatory diseases. These mechanisms include effects on the cellular compartment and on the humoral compartment. Thus, IVIg impacts on dendritic cells, macrophages, neutrophils, basophils, NK cells, and B and T lymphocytes. Several studies have emphasized that the antiinflammatory effect of IVIg is dependent on α2,6-sialylation of the N-linked glycan on asparagine-297 of the Fc portion of IgG. However, recent reports have questioned the necessity of sialylated Fc and the role of FcγRIIB in IVIg-mediated antiinflammatory effects. In view of the critical role played by Th17 cells in several autoimmune pathologies and the increasing use of IVIg in several of these conditions, by using neuraminidase-treated, desialylated IVIg, we addressed whether the α2,6-sialylation of IgG is essential for the beneficial effect of IVIg in experimental autoimmune encephalomyelitis (EAE), a Th17-driven condition, and for the reciprocal modulation of helper T-cell subsets. We observed no difference in the ability of IVIg to ameliorate EAE irrespective of its sialylation. Our findings thus show that sialylation of IVIg is not necessary for IVIg-mediated amelioration of EAE or for downregulation of Th17 cells and upregulation of regulatory T cells.


Assuntos
Imunoglobulinas Intravenosas/farmacologia , Linfócitos T Auxiliares-Indutores/efeitos dos fármacos , Sequência de Aminoácidos , Animais , Encefalomielite Autoimune Experimental/tratamento farmacológico , Encefalomielite Autoimune Experimental/etiologia , Feminino , Fragmentos Fc das Imunoglobulinas/metabolismo , Imunoglobulinas Intravenosas/uso terapêutico , Camundongos , Camundongos Endogâmicos C57BL , Dados de Sequência Molecular , Ácido N-Acetilneuramínico/metabolismo , Linfócitos T Auxiliares-Indutores/imunologia , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/imunologia , Células Th17/fisiologia
2.
Cell Microbiol ; 16(10): 1533-48, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24798694

RESUMO

Plasmodium sporozoites are transmitted by Anopheles mosquitoes and first infect the liver of their mammalian host, where they develop as liver stages before the onset of erythrocytic infection and malaria symptoms. Sporozoite entry into hepatocytes is an attractive target for anti-malarial prophylactic strategies but remains poorly understood at the molecular level. Apicomplexan parasites invade host cells by forming a parasitophorous vacuole that is essential for parasite development, a process that involves secretion of apical organelles called rhoptries. We previously reported that the host membrane protein CD81 is required for infection by Plasmodium falciparum and Plasmodium yoelii sporozoites. CD81 acts at an early stage of infection, possibly at the entry step, but the mechanisms involved are still unknown. To investigate the role of CD81 during sporozoite entry, we generated transgenic P. yoelii parasites expressing fluorescent versions of three known rhoptry proteins, RON2, RON4 and RAP2/3. We observed that RON2 and RON4 are lost following rhoptry discharge during merozoite and sporozoite entry. In contrast, our data indicate that RAP2/3 is secreted into the parasitophorous vacuole during infection. We further show that sporozoite rhoptry discharge occurs only in the presence of CD81, providing the first direct evidence for a role of CD81 during sporozoite productive invasion.


Assuntos
Interações Hospedeiro-Parasita/fisiologia , Plasmodium yoelii/patogenicidade , Proteínas de Protozoários/metabolismo , Esporozoítos/patologia , Tetraspanina 28/metabolismo , Animais , Linhagem Celular , Feminino , Proteínas de Fluorescência Verde/genética , Células Hep G2 , Hepatócitos/parasitologia , Humanos , Proteínas Luminescentes/genética , Malária , Camundongos , Camundongos Endogâmicos BALB C , Organismos Geneticamente Modificados , Plasmodium yoelii/genética , Proteínas de Protozoários/biossíntese , Proteínas de Protozoários/genética , Vacúolos/patologia , Proteína Vermelha Fluorescente
3.
J Immunol ; 190(9): 4535-41, 2013 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-23526819

RESUMO

Despite an increasing use of high-dose therapy of i.v. gammaglobulin (IVIg) in the treatment of various T cell- and Ab-mediated inflammatory and autoimmune diseases, comprehension of the mechanisms underlying its therapeutic benefit has remained a major challenge. Particularly, the effect of IVIg in T cell-mediated autoimmune conditions remains unexplored. Using an actively induced experimental autoimmune encephalomyelitis model, a T cell-mediated autoimmune condition, we demonstrate that IVIg inhibits the differentiation of naive CD4 T cells into encephalitogenic subsets (Th1 and Th17 cells) and concomitantly induces an expansion of Foxp3(+) regulatory T cells. Further, IVIg renders effector T cells less pathogenic by decreasing the expression of encephalitogenic molecular players like GM-CSF and podoplanin. Intriguingly and contrary to the current arguments, the inhibitory FcγRIIB is dispensable for IVIg-mediated reciprocal modulation of effector and regulatory CD4 subsets. Additionally, F(ab')2 fragments also retained this function of IVIg. IVIg or F(ab')2 fragments decrease the sphingosine-1 phosphate receptor on CD4 cells, thus sequestering these cells in the draining lymph nodes and decreasing their infiltration into the CNS. Our study reveals a novel role of Igs in the modulation of polarization and trafficking of T lymphocytes, accounting for the observed beneficial effect in IVIg therapy.


Assuntos
Linfócitos T CD4-Positivos/efeitos dos fármacos , Encefalite/imunologia , Encefalomielite Autoimune Experimental/tratamento farmacológico , Imunoglobulinas Intravenosas/farmacologia , Receptores de Lisoesfingolipídeo/metabolismo , Serina-Treonina Quinases TOR/metabolismo , Administração Intravenosa/métodos , Animais , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/metabolismo , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/imunologia , Encefalite/tratamento farmacológico , Encefalite/metabolismo , Encefalomielite Autoimune Experimental/imunologia , Encefalomielite Autoimune Experimental/metabolismo , Feminino , Fator Estimulador de Colônias de Granulócitos e Macrófagos/imunologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/metabolismo , Imunoglobulinas Intravenosas/imunologia , Glicoproteínas de Membrana/imunologia , Glicoproteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Receptores de IgG/imunologia , Receptores de IgG/metabolismo , Receptores de Lisoesfingolipídeo/imunologia , Receptores de Esfingosina-1-Fosfato , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/imunologia , Linfócitos T Reguladores/metabolismo , Serina-Treonina Quinases TOR/imunologia , Células Th1/efeitos dos fármacos , Células Th1/imunologia , Células Th1/metabolismo , Células Th17/efeitos dos fármacos , Células Th17/imunologia , Células Th17/metabolismo
4.
J Autoimmun ; 39(3): 168-72, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22704540

RESUMO

Intravenous immunoglobulin (IVIg) is a therapeutic preparation consisting of pools of normal, polyspecific IgG antibodies obtained from plasma of several thousand healthy individuals. In addition to its use in primary and secondary immune deficiency, IVIg is increasingly used in the therapy of a large number of autoimmune conditions. Despite its successful use in immunopathologies for over two decades, the precise mechanisms underlying the therapeutic benefit have not been fully elucidated. We and others have demonstrated that IVIg inhibits the antigen uptake and presentation by dendritic cells (DC). Here we report that IVIg-mediated inhibition of uptake and processing of antigens is associated with an increased accumulation of lipid as analyzed by flow cytometry and electron microscopy. As accumulation of lipids in DC is known to impart tolerogenic properties, these findings unravel novel link between antibodies and intracellular physiology of innate cells and may further uncover novel immunoregulatory mechanisms of IVIg in auto-inflammatory diseases.


Assuntos
Apresentação de Antígeno/efeitos dos fármacos , Antígenos/metabolismo , Células Dendríticas/efeitos dos fármacos , Endocitose/efeitos dos fármacos , Imunoglobulinas Intravenosas/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Apresentação de Antígeno/imunologia , Antígenos/imunologia , Diferenciação Celular , Células Cultivadas , Células Dendríticas/citologia , Células Dendríticas/imunologia , Endocitose/imunologia , Citometria de Fluxo , Corantes Fluorescentes , Humanos , Metabolismo dos Lipídeos/imunologia , Lipídeos , Microscopia Eletrônica de Transmissão , Monócitos/citologia , Monócitos/imunologia
6.
Elife ; 62017 05 16.
Artigo em Inglês | MEDLINE | ID: mdl-28506360

RESUMO

Plasmodium sporozoites, the mosquito-transmitted forms of the malaria parasite, first infect the liver for an initial round of replication before the emergence of pathogenic blood stages. Sporozoites represent attractive targets for antimalarial preventive strategies, yet the mechanisms of parasite entry into hepatocytes remain poorly understood. Here we show that the two main species causing malaria in humans, Plasmodium falciparum and Plasmodium vivax, rely on two distinct host cell surface proteins, CD81 and the Scavenger Receptor BI (SR-BI), respectively, to infect hepatocytes. By contrast, CD81 and SR-BI fulfil redundant functions during infection by the rodent parasite P. berghei. Genetic analysis of sporozoite factors reveals the 6-cysteine domain protein P36 as a major parasite determinant of host cell receptor usage. Our data provide molecular insights into the invasion pathways used by different malaria parasites to infect hepatocytes, and establish a functional link between a sporozoite putative ligand and host cell receptors.


Assuntos
Proteínas de Membrana/metabolismo , Plasmodium berghei/crescimento & desenvolvimento , Plasmodium falciparum/crescimento & desenvolvimento , Plasmodium vivax/crescimento & desenvolvimento , Proteínas de Protozoários/metabolismo , Esporozoítos/crescimento & desenvolvimento , Animais , Linhagem Celular , Endocitose , Hepatócitos/parasitologia , Interações Hospedeiro-Patógeno , Humanos , Roedores , Receptores Depuradores Classe B/metabolismo , Tetraspanina 28/metabolismo
7.
Cell Host Microbe ; 18(5): 593-603, 2015 Nov 11.
Artigo em Inglês | MEDLINE | ID: mdl-26607162

RESUMO

Plasmodium sporozoites are deposited in the host skin by Anopheles mosquitoes. The parasites migrate from the dermis to the liver, where they invade hepatocytes through a moving junction (MJ) to form a replicative parasitophorous vacuole (PV). Malaria sporozoites need to traverse cells during progression through host tissues, a process requiring parasite perforin-like protein 1 (PLP1). We find that sporozoites traverse cells inside transient vacuoles that precede PV formation. Sporozoites initially invade cells inside transient vacuoles by an active MJ-independent process that does not require vacuole membrane remodeling or release of parasite secretory organelles typically involved in invasion. Sporozoites use pH sensing and PLP1 to exit these vacuoles and avoid degradation by host lysosomes. Next, parasites enter the MJ-dependent PV, which has a different membrane composition, precluding lysosome fusion. The malaria parasite has thus evolved different strategies to evade host cell defense and establish an intracellular niche for replication.


Assuntos
Malária/patologia , Malária/parasitologia , Plasmodium berghei/metabolismo , Plasmodium yoelii/metabolismo , Esporozoítos/patologia , Esporozoítos/parasitologia , Vacúolos/parasitologia , Animais , Anopheles/parasitologia , Células Hep G2 , Hepatócitos/patologia , Hepatócitos/ultraestrutura , Humanos , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Plasmodium berghei/crescimento & desenvolvimento , Plasmodium berghei/ultraestrutura , Plasmodium yoelii/crescimento & desenvolvimento , Plasmodium yoelii/ultraestrutura , Proteínas de Protozoários/metabolismo , Esporozoítos/metabolismo , Vacúolos/metabolismo , Vacúolos/ultraestrutura
8.
Sci Rep ; 4: 4760, 2014 Apr 23.
Artigo em Inglês | MEDLINE | ID: mdl-24755823

RESUMO

Experimental genetics have been widely used to explore the biology of the malaria parasites. The rodent parasites Plasmodium berghei and less frequently P. yoelii are commonly utilised, as their complete life cycle can be reproduced in the laboratory and because they are genetically tractable via homologous recombination. However, due to the limited number of drug-selectable markers, multiple modifications of the parasite genome are difficult to achieve and require large numbers of mice. Here we describe a novel strategy that combines positive-negative drug selection and flow cytometry-assisted sorting of fluorescent parasites for the rapid generation of drug-selectable marker-free P. berghei and P. yoelii mutant parasites expressing a GFP or a GFP-luciferase cassette, using minimal numbers of mice. We further illustrate how this new strategy facilitates phenotypic analysis of genetically modified parasites by fluorescence and bioluminescence imaging of P. berghei mutants arrested during liver stage development.


Assuntos
Antimaláricos/farmacologia , Malária/parasitologia , Testes de Sensibilidade Parasitária/métodos , Plasmodium/efeitos dos fármacos , Plasmodium/genética , Animais , Animais Geneticamente Modificados , Antimaláricos/uso terapêutico , Resistência a Medicamentos/genética , Feminino , Expressão Gênica , Genes Reporter , Marcadores Genéticos , Humanos , Estágios do Ciclo de Vida , Fígado/efeitos dos fármacos , Fígado/parasitologia , Medições Luminescentes/métodos , Malária/tratamento farmacológico , Camundongos , Plasmodium/crescimento & desenvolvimento , Plasmodium berghei/efeitos dos fármacos , Plasmodium berghei/genética , Recombinação Genética
9.
PLoS One ; 6(10): e26469, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22065996

RESUMO

BACKGROUND: Polymorphonuclear neutrophils (PMN) play a key role in host defences against invading microorganisms but can also potentiate detrimental inflammatory reactions in case of excessive or misdirected responses. Intravenous immunoglobulins (IVIg) are used to treat patients with immune deficiencies and, at higher doses, in autoimmune, allergic and systemic inflammatory disorders. METHODOLOGY/PRINCIPAL FINDINGS: We used flow cytometry to examine the effects of IVIg on PMN functions and survival, using whole-blood conditions in order to avoid artifacts due to isolation procedures. IVIg at low concentrations induced PMN activation, as reflected by decreased L-selectin and increased CD11b expression at the PMN surface, oxidative burst enhancement, and prolonged cell survival. In contrast, IVIg at higher concentrations inhibited LPS-induced CD11b degranulation and oxidative burst priming, and counteracted LPS-induced PMN lifespan prolongation. CONCLUSIONS/SIGNIFICANCE: IVIg appears to have differential, concentration-dependent effects on PMN, possibly supporting the use of IVIg as either an anti-microbial or an anti-inflammatory agent.


Assuntos
Anti-Infecciosos/farmacologia , Anti-Inflamatórios/farmacologia , Imunoglobulinas Intravenosas/farmacologia , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Apoptose/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Humanos , Lipopolissacarídeos/farmacologia , Ativação de Neutrófilo/efeitos dos fármacos , Neutrófilos/citologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA